#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | NCI Cancer Stats @NCICancerStats Every year, ~7,330 lung cancer deaths occur among adult nonsmokers in the United States as a result of #secondhandsmoke. Check out NCI Map Stories for more info: https://t.co/1GvSpfGmUy #LCSM https://t.co/vh3MkX0osA |
 | Janet Freeman-Daily @JFreemanDaily Welcome to the first #LCSM Chat of 2019! We’ve shifted to monthly chats this year. Tonight we’re hosting a collaborative chat across all cancer hashtag communities #hcsm #bcsm #btsm #gyncsm #mmsm #ayacsm, etc. To participate, include #LCSM in all your tweets. |
| Janet Freeman-Daily @JFreemanDaily @SunshineKK68 Yep, we're on! Here we go! #LCSM |
| Janet Freeman-Daily @JFreemanDaily Tonight’s chat is titled “Immunotherapy: What patients need to know.” More info at https://t.co/yzwKSTFWfl #LCSM |
 | Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Tim here. #LCSM |
 | #LCSM Chat @lcsmchat RT @JFreemanDaily: Welcome to the first #LCSM Chat of 2019! We’ve shifted to monthly chats this year. Tonight we’re hosting a collaborative chat across all cancer hashtag communities #hcsm #bcsm #btsm #gyncsm #mmsm #ayacsm, etc. To participate, include #LCSM in all your tweets. |
 | Faces of Lung Cancer @LungCancerFaces RT @JFreemanDaily: Welcome to the first #LCSM Chat of 2019! We’ve shifted to monthly chats this year. Tonight we’re hosting a collaborative chat across all cancer hashtag communities #hcsm #bcsm #btsm #gyncsm #mmsm #ayacsm, etc. To participate, include #LCSM in all your tweets. |
| Janet Freeman-Daily @JFreemanDaily We'll get started in a few minutes -- please take a moment to introduce yourselves #LCSM |
| Faces of Lung Cancer @LungCancerFaces RT @JFreemanDaily: Tonight’s chat is titled “Immunotherapy: Tonight’s chat is titled “Immunotherapy: What patients need to know.” More info at https://t.co/yzwKSTFWfl #LCSM |
 | Christine Qiong Wu @CQiongWu I'm here. #lcsm |
 | Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh I'm here #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We'll get started in a few minutes -- please take a moment to introduce yourselves #LCSM |
| #LCSM Chat @lcsmchat @wi_qiong Welcome Christine! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Tonight’s chat is titled “Immunotherapy: Tonight’s chat is titled “Immunotherapy: What patients need to know.” More info at https://t.co/yzwKSTFWfl #LCSM |
| #LCSM Chat @lcsmchat @Kamacintosh Hi Kim! #lcsm |
| Janet Freeman-Daily @JFreemanDaily Our special guest is Lisa Rezende (@LisaRezende1), @UofA Assistant Professor of Practice in Molecular and Cellular Biology, cancer advocate, BRCA previvor, daughter of a long-term ovarian cancer survivor, and caregiver for a stepmother with metastatic breast cancer. #LCSM |
| #LCSM Chat @lcsmchat Deana @LungCancerFaces tweeting from the @lcsmchat account. #LCSM |
 | KC Dill @kasedill Hello from TX excited to join everyone .#LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Our special guest is Lisa Rezende (@LisaRezende1), @UofA Assistant Professor of Practice in Molecular and Cellular Biology, cancer advocate, BRCA previvor, daughter of a long-term ovarian cancer survivor, and caregiver for a stepmother with metastatic breast cancer. #LCSM |
 | Lisa Rezende @LisaRezende1 I'm Lisa. I teach intro biology and science outreach. I've worked and/or volunteered as a hereditary cancer patient advocate since 2011. #LCSM |
| Faces of Lung Cancer @LungCancerFaces RT @JFreemanDaily: Our special guest is Lisa Rezende (@LisaRezende1), @UofA Assistant Professor of Practice in Molecular and Cellular Biology, cancer advocate, BRCA previvor, daughter of a long-term ovarian cancer survivor, and caregiver for a stepmother with metastatic breast cancer. #LCSM |
| Janet Freeman-Daily @JFreemanDaily I’m your moderator Janet Freeman-Daily: writer (https://t.co/OBCc87ZwkG), science geek, stage IV #lungcancer patient/activist #LCSM |
| Christine Qiong Wu @CQiongWu Hello, Bob, I see you are here. #lcsm |
| #LCSM Chat @lcsmchat @kasedill Welcome! Thanks for joining. #lcsm |
 | Sally James @jamesian @JFreemanDaily Hi, I'm not staying for chat, but explained the value of #LCSM to an audience of about 50 on Tuesday in a suburb of #seattle. Hope some new members join. (My name is Sally, and I'm a journalist who has written about patients on social) |
 | Bob Steele @steele_bob Bob here from chilly Greensboro, NC #lcsm |
| #LCSM Chat @lcsmchat RT @LisaRezende1: I'm Lisa. I teach intro biology and science outreach. I've worked and/or volunteered as a hereditary cancer patient advocate since 2011. #LCSM |
 | Jill Feldman @jillfeldman4 Hello from very cold Chicago! #LCSM |
 | Anita Figueras @scifiknitter Good evening all! Anita here. #LCSM |
| #LCSM Chat @lcsmchat @LisaRezende1 Welcome! Thanks for being our expert this evening. #lcsm |
 | OurWarOnCancer @OurWarOnCancer RT @andrewjayloftis: Updates on my medical misadventures don't lend themselves to character limits, so I'll post the screenshot from Facebook #lcsm https://t.co/7oTFFyW97r |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: I’m your moderator Janet Freeman-Daily: I’m your moderator Janet Freeman-Daily: writer (https://t.co/OBCc87ZwkG), science geek, stage IV #lungcancer patient/activist #LCSM |
 | Peggy Dennis @peggyddennis Hello from Denver #lcsm |
| KC Dill @kasedill @jillfeldman4 Hi Jill #lcsm |
 | Dee Sparacio @womenofteal @JFreemanDaily Dee #ovca survivor, Resaerch advocate and #gyncsm co-moderator with @btrfly12 and still forgot to use the hashtag #lcsm |
| Christine Qiong Wu @CQiongWu Hello, Janet. #lcsm |
| #LCSM Chat @lcsmchat @jamesian @JFreemanDaily Thank you, Sally! #lcsm |
 | Marilyn Kempf @MarilynKempf RT @LungCancerFaces: And 4,000+ Americans have died of lung cancer by day 10 of 2019. It's not a competition. It's a #NationalEmergency. MBC & LC should be front & center in our country. Over 5,000 voters gone since the beginning of the year. Does anyone care? #bcsm #lcsm @realDonaldTrump @JoeBiden |
| #LCSM Chat @lcsmchat RT @jamesian: @JFreemanDaily Hi, I'm not staying for chat, but explained the value of #LCSM to an audience of about 50 on Tuesday in a suburb of #seattle. Hope some new members join. (My name is Sally, and I'm a journalist who has written about patients on social) |
| OurWarOnCancer @OurWarOnCancer RT @JFreemanDaily: Our special guest is Lisa Rezende (@LisaRezende1), @UofA Assistant Professor of Practice in Molecular and Cellular Biology, cancer advocate, BRCA previvor, daughter of a long-term ovarian cancer survivor, and caregiver for a stepmother with metastatic breast cancer. #LCSM |
| #LCSM Chat @lcsmchat @steele_bob Hey, Bob! Hope you and your wife are OK. #lcsm |
| #LCSM Chat @lcsmchat @jillfeldman4 Hey, Jill! #lcsm |
| Janet Freeman-Daily @JFreemanDaily @LisaRezende1 Welcome Lisa! #LCSM |
| #LCSM Chat @lcsmchat @scifiknitter Hello gorgeous! #lcsm |
 | Michigan_Yallers ~ Jennifer Aiken 🇺🇲 @Michigan_Yaller RT @JFreemanDaily: Our special guest is Lisa Rezende (@LisaRezende1), @UofA Assistant Professor of Practice in Molecular and Cellular Biology, cancer advocate, BRCA previvor, daughter of a long-term ovarian cancer survivor, and caregiver for a stepmother with metastatic breast cancer. #LCSM |
| #LCSM Chat @lcsmchat @peggyddennis Hi Peggy! #lcsm |
| Lisa Rezende @LisaRezende1 Thanks for the invitation! I am not a health care provider or a researcher. My expertise is helping patients understand their cancer and options. I believe that you should not need a degree in biology to participate in shared decision making with your health care team. #LCSM |
| #LCSM Chat @lcsmchat @womenofteal @JFreemanDaily @btrfly12 Welcome Dee! #lcsm |
| #LCSM Chat @lcsmchat RT @LisaRezende1: Thanks for the invitation! I am not a health care provider or a researcher. My expertise is helping patients understand their cancer and options. I believe that you should not need a degree in biology to participate in shared decision making with your health care team. #LCSM |
| Janet Freeman-Daily @JFreemanDaily If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb #LCSM |
| KC Dill @kasedill RT @LisaRezende1: Thanks for the invitation! I am not a health care provider or a researcher. My expertise is helping patients understand their cancer and options. I believe that you should not need a degree in biology to participate in shared decision making with your health care team. #LCSM |
| Janet Freeman-Daily @JFreemanDaily @LisaRezende1 Absolutely awesome! #LCSM |
 | Geri Massa @GeriGerim13 Hi ya’ll .... #LCSM |
| Janet Freeman-Daily @JFreemanDaily Please remember to use #lcsm in all your tweets so others participating in the chat can see them #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb #LCSM |
| Janet Freeman-Daily @JFreemanDaily If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #LCSM |
| #LCSM Chat @lcsmchat @GeriGerim13 Hey Geri! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Please remember to use #lcsm in all your tweets so others participating in the chat can see them #LCSM |
| Janet Freeman-Daily @JFreemanDaily Note: Twitter allows tweets up to 280 characters, but some tweetchat apps (like https://t.co/A2M7gXQ66L) will not display tweets longer than 140. #LCSM |
 | Lung Cancer Sux @LungCancerSux Happy New Year! #lcsm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh HI Jill,! #lcsm |
| Faces of Lung Cancer @LungCancerFaces RT @JFreemanDaily: If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb #LCSM |
| Janet Freeman-Daily @JFreemanDaily I will announce FIVE topics (T1 T2 etc). Pls label your answers with T1, T2, etc to make transcript easier to follow. #LCSM |
 | Loves Mashed Potatoes @glostaMAssachu #LCSM |
| #LCSM Chat @lcsmchat @LungCancerSux Welcome! #lcsm |
| KC Dill @kasedill @LungCancerSux Happy New Year #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #LCSM |
| KC Dill @kasedill RT @JFreemanDaily: I will announce FIVE topics (T1 T2 etc). Pls label your answers with T1, T2, etc to make transcript easier to follow. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Note: Note: Twitter allows tweets up to 280 characters, but some tweetchat apps (like https://t.co/A2M7gXQ66L) will not display tweets longer than 140. #LCSM |
| Janet Freeman-Daily @JFreemanDaily T1: Why doesn’t the immune system prevent cancer? #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: I will announce FIVE topics (T1 T2 etc). Pls label your answers with T1, T2, etc to make transcript easier to follow. #LCSM |
| #LCSM Chat @lcsmchat @wildwestannie We see you! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: T1: Why doesn’t the immune system prevent cancer? #LCSM |
| Bob Steele @steele_bob RT @JFreemanDaily: T1: T1: Why doesn’t the immune system prevent cancer? #LCSM |
| Jill Feldman @jillfeldman4 RT @JFreemanDaily: T1: T1: Why doesn’t the immune system prevent cancer? #LCSM |
 | Stephen V Liu, MD @StephenVLiu T1: it does prevent cancer - but cancers can evolve many different ways to escape immune surveillance - such as expression of PDL1 among others #LCSM |
| Jill Feldman @jillfeldman4 T1 Cancer finds a way to evade our immune system #LCSM |
| Lung Cancer Sux @LungCancerSux Where is @BrendonStilesMD when we need him #lcsm |
| #LCSM Chat @lcsmchat RT @StephenVLiu: T1: T1: it does prevent cancer - but cancers can evolve many different ways to escape immune surveillance - such as expression of PDL1 among others #LCSM |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T1 Cancer finds a way to evade our immune system #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T1: T1: Why doesn’t the immune system prevent cancer? #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @StephenVLiu: T1: T1: it does prevent cancer - but cancers can evolve many different ways to escape immune surveillance - such as expression of PDL1 among others #LCSM |
| #LCSM Chat @lcsmchat @StephenVLiu Elaborate, please? #lcsm |
| Lisa Rezende @LisaRezende1 T1 A properly functioning immune system must recognize and eliminate pathogens (bacteria, viruses, and parasites) and harmful cells without hurting healthy cells. #LCSM |
| Janet Freeman-Daily @JFreemanDaily Our cells have tumor suppression mechanisms, but sometimes they don't recognize a cell is "Not Me." #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T1 A properly functioning immune system must recognize and eliminate pathogens (bacteria, viruses, and parasites) and harmful cells without hurting healthy cells. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Our cells have tumor suppression mechanisms, but sometimes they don't recognize a cell is "Not Me." #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Often cancer cells molecularly "trick" the immune system into not recognizing them as abnormal cells. #LCSM |
| Lisa Rezende @LisaRezende1 T1. Cells have markers on their surface, called antigens, that help the immune system determine if the cell is healthy or not. #LCSM |
| Jill Feldman @jillfeldman4 T1 But it's puzzling and don't know exactly why it happens in some people and not others. Where/what is the breakdown and why? #LCSM |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh actually use immune cells to facilitate their attack on the body. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Our cells have tumor suppression mechanisms, but sometimes they don't recognize a cell is "Not Me." #LCSM |
 | Ildiko Medve @MedveIldiko RT @lgreco_ny: Podcast in which I'm featured talking about patient advocacy and clinical trials. @MassBio @bjork5 #lcsm https://t.co/T99jkY5Fkd |
| Bob Steele @steele_bob RT @LisaRezende1: T1. Cells have markers on their surface, called antigens, that help the immune system determine if the cell is healthy or not. #LCSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Often cancer cells molecularly "trick" the immune system into not recognizing them as abnormal cells. #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T1. Cells have markers on their surface, called antigens, that help the immune system determine if the cell is healthy or not. #LCSM |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T1 But it's puzzling and don't know exactly why it happens in some people and not others. Where/what is the breakdown and why? #LCSM |
| Lisa Rezende @LisaRezende1 If the immune system recognizes the marker as belong there (sometimes called self) then it does not attack the cell. If the immune systems does not then it will mount an immune response. #LCSM |
| Bob Steele @steele_bob RT @lgreco_ny: Podcast in which I'm featured talking about patient advocacy and clinical trials. @MassBio @bjork5 #lcsm https://t.co/T99jkY5Fkd |
| Stephen V Liu, MD @StephenVLiu @lcsmchat Our immune system will recognize and eliminate cancers - cancers that happen to have certain characteristics that allow escape (by chance) are the ones that survive. Our system selects for these cancers (immunoediting). #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: If the immune system recognizes the marker as belong there (sometimes called self) then it does not attack the cell. If the immune systems does not then it will mount an immune response. #LCSM |
| Janet Freeman-Daily @JFreemanDaily I know @LisaRezende1 has some cool slides prepared for this chat--apparently her Internet connection isn't letting the images post. Pooh. Hopefully she can post them later. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @LisaRezende1: If the immune system recognizes the marker as belong there (sometimes called self) then it does not attack the cell. If the immune systems does not then it will mount an immune response. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @StephenVLiu: @lcsmchat Our immune system will recognize and eliminate cancers - cancers that happen to have certain characteristics that allow escape (by chance) are the ones that survive. Our system selects for these cancers (immunoediting). #LCSM |
| Lisa Rezende @LisaRezende1 T1. Cancer cells develop when a series of changes to the cell's DNA affect the mechanisms that control how the cell divides. Some of these changes lead to new marker on the cell surface. #LCSM |
| Lisa Rezende @LisaRezende1 T1. If the immune system identifies the new marker as abonormal, it will attack and eliminate the cancer cell. #LCSM |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @lcsmchat Our immune system will recognize and eliminate cancers - cancers that happen to have certain characteristics that allow escape (by chance) are the ones that survive. Our system selects for these cancers (immunoediting). #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: I know @LisaRezende1 has some cool slides prepared for this chat--apparently her Internet connection isn't letting the images post. Pooh. Hopefully she can post them later. #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T1. Cancer cells develop when a series of changes to the cell's DNA affect the mechanisms that control how the cell divides. Some of these changes lead to new marker on the cell surface. #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T1. If the immune system identifies the new marker as abonormal, it will attack and eliminate the cancer cell. #LCSM |
| Dee Sparacio @womenofteal RT @LisaRezende1: If the immune system recognizes the marker as belong there (sometimes called self) then it does not attack the cell. If the immune systems does not then it will mount an immune response. #LCSM |
| Dee Sparacio @womenofteal RT @LisaRezende1: T1. Cancer cells develop when a series of changes to the cell's DNA affect the mechanisms that control how the cell divides. Some of these changes lead to new marker on the cell surface. #LCSM |
| Lisa Rezende @LisaRezende1 T1. In some cases, the immune system cannot eliminate the cancer cell but can keep the cell from growing out of control. This phase, where tumor growth is kept under control is called equilibrium. #LCSM |
| Janet Freeman-Daily @JFreemanDaily Our cells' DNA acquire mutations over time as they make copies of themselves, and/or are exposed to something that causes them to mutate. The immune system SHOULD recognize those cells as "Not Me," but for some reason that doesn't always work. #LCSM |
| Stephen V Liu, MD @StephenVLiu By understanding how cancers escape immune surveillance, we can develop strategies to restore immune control. Checkpoint inhibitors are just the start! #LCSM |
| Lisa Rezende @LisaRezende1 T1. If a tumor has formed and spread, then it has developed a way to evade the immune system-- sometimes called escape. #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T1. In some cases, the immune system cannot eliminate the cancer cell but can keep the cell from growing out of control. This phase, where tumor growth is kept under control is called equilibrium. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Our cells' DNA acquire mutations over time as they make copies of themselves, and/or are exposed to something that causes them to mutate. The immune system SHOULD recognize those cells as "Not Me," but for some reason that doesn't always work. #LCSM |
| #LCSM Chat @lcsmchat RT @StephenVLiu: By understanding how cancers escape immune surveillance, we can develop strategies to restore immune control. Checkpoint inhibitors are just the start! #LCSM |
| Janet Freeman-Daily @JFreemanDaily T2: What types of immunotherapy have been approved? #LCSM |
| Dee Sparacio @womenofteal RT @StephenVLiu: By understanding how cancers escape immune surveillance, we can develop strategies to restore immune control. Checkpoint inhibitors are just the start! #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T1. If a tumor has formed and spread, then it has developed a way to evade the immune system-- sometimes called escape. #LCSM |
| KC Dill @kasedill RT @StephenVLiu: By understanding how cancers escape immune surveillance, we can develop strategies to restore immune control. Checkpoint inhibitors are just the start! #LCSM |
| Dee Sparacio @womenofteal RT @JFreemanDaily: Our cells' DNA acquire mutations over time as they make copies of themselves, and/or are exposed to something that causes them to mutate. The immune system SHOULD recognize those cells as "Not Me," but for some reason that doesn't always work. #LCSM |
| Lisa Rezende @LisaRezende1 T1. Immunotherapy treatments help the immune system regain control of the cancer cells. #LCSM |
| Jill Feldman @jillfeldman4 RT @StephenVLiu: By understanding how cancers escape immune surveillance, we can develop strategies to restore immune control. Checkpoint inhibitors are just the start! #LCSM |
 | Emily K. Drake @EK_Drake RT @JFreemanDaily: Welcome to the first #LCSM Chat of 2019! We’ve shifted to monthly chats this year. Tonight we’re hosting a collaborative chat across all cancer hashtag communities #hcsm #bcsm #btsm #gyncsm #mmsm #ayacsm, etc. To participate, include #LCSM in all your tweets. |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T1. Immunotherapy treatments help the immune system regain control of the cancer cells. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T2: T2: What types of immunotherapy have been approved? #LCSM |
| Lisa Rezende @LisaRezende1 T2. Just as there are different types of chemotherapies, there are different types of immunotherapies. #LCSM |
| Bob Steele @steele_bob Surprised to learn that immuno drugs are "targeted" like precision tx. #lcsm |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T2. Just as there are different types of chemotherapies, there are different types of immunotherapies. #LCSM |
| #LCSM Chat @lcsmchat RT @steele_bob: Surprised to learn that immuno drugs are "targeted" like precision tx. #lcsm |
| Dee Sparacio @womenofteal Checkpoint inhibitors that target PD-1 like Keytruda is one that comes to mind. #lcsm |
| Anita Figueras @scifiknitter RT @StephenVLiu: By understanding how cancers escape immune surveillance, we can develop strategies to restore immune control. Checkpoint inhibitors are just the start! #LCSM |
| Janet Freeman-Daily @JFreemanDaily Lisa's wonderful prepared tweets are not going through for some reasons ... #LCSM |
| Lisa Rezende @LisaRezende1 T2. While all of these therapies help the immune system fight cancer, different types have been approved for different cancers. The patient experience will depend on the type of therapy they recieve. #LCSM |
| #LCSM Chat @lcsmchat RT @womenofteal: Checkpoint inhibitors that target PD-1 like Keytruda is one that comes to mind. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Lisa's wonderful prepared tweets are not going through for some reasons ... #LCSM |
 | Brendon Stiles @BrendonStilesMD Joining in from road with bad connection! Just spent all day talking lung cancer. How is everyone?! I miss all of you. Happy new year! #lcsm |
| Christine Qiong Wu @CQiongWu How does PD-1 and PD-?1 work? #lcsm |
 | SunshineKK @SunshineKK68 How does Keytruda work with chemotherapies even without PDL1? #lcsm |
| KC Dill @kasedill T2 Nivolumab is another approved checkpoint inhibitor. #lcsm |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T2. While all of these therapies help the immune system fight cancer, different types have been approved for different cancers. The patient experience will depend on the type of therapy they recieve. #LCSM |
| Bob Steele @steele_bob How do immuno drugs differ from antibiotics? #lcsm |
| Lisa Rezende @LisaRezende1 T2. Adoptive cell transfer therapies use the patient's own immune cell. An example is CAR T-cell therapy, which is approved for some blood cancers. #LCSM |
 | Nicole Kuderer, MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏 @NicoleKuderer RT @StephenVLiu: By understanding how cancers escape immune surveillance, we can develop strategies to restore immune control. Checkpoint inhibitors are just the start! #LCSM |
| Brendon Stiles @BrendonStilesMD Where are we in this whole conversation? #lcsm |
 | Aparna Hegde, MD @notahedge T1 T-cells are like cops, patrolling the body for bad guys which may be bacteria/viruses/even 🦀 cells. Normal cells express proteins on their surface to let the T cells knw tht they belong in the body ex: PDL1. 🦀 cells escape killing by Tcells by expressing the same PDL1. #LCSM |
 | Lecia Sequist, MD, MPH @LeciaSequist Hi twitter buddies! Joining the chat briefly from Boston. Lung cancer medical oncologist. Immune therapy has been a game changer in lung cancer (yes, I said game changer) #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @LisaRezende1: T2. Adoptive cell transfer therapies use the patient's own immune cell. An example is CAR T-cell therapy, which is approved for some blood cancers. #LCSM |
| KC Dill @kasedill @BrendonStilesMD Hello T2 #LCSM |
| #LCSM Chat @lcsmchat @BrendonStilesMD We miss you, too! Don't worry--you're moderating the Feb chat. xo #lcsm |
| Loves Mashed Potatoes @glostaMAssachu What is the checkpoint that is inhibited? #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @notahedge: T1 T-cells are like cops, patrolling the body for bad guys which may be bacteria/viruses/even 🦀 cells. Normal cells express proteins on their surface to let the T cells knw tht they belong in the body ex: PDL1. 🦀 cells escape killing by Tcells by expressing the same PDL1. #LCSM |
| Lisa Rezende @LisaRezende1 T2. Most patients think of vaccines in terms of prevention. In immunotherapy, cancer vaccines are used for treatment. These are often called therapeutic vaccines. #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: Hi twitter buddies! Joining the chat briefly from Boston. Lung cancer medical oncologist. Immune therapy has been a game changer in lung cancer (yes, I said game changer) #lcsm |
| KC Dill @kasedill @LeciaSequist Hello! I will take game changer.. #LCSM |
 | MaryAnn Bradley @Dollybrad @BrendonStilesMD Happy new year #LCSM |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD We're on T2, but Twitter is misbehaving so we're behind on our tweets. #LCSM |
| #LCSM Chat @lcsmchat @LeciaSequist Yippee! Hi there. #lcsm |
| Lisa Rezende @LisaRezende1 T2. Cancer therapeutic vaccines train the immune system to recognize and eliminate cancer cells. Most are still in clinical trials but there is one approved for prostate cancer. #LCSM |
| Brendon Stiles @BrendonStilesMD @lcsmchat Going to bring the A-game and get the A-listers out in force. #lcsm |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T2. Adoptive cell transfer therapies use the patient's own immune cell. An example is CAR T-cell therapy, which is approved for some blood cancers. #LCSM |
| #LCSM Chat @lcsmchat RT @notahedge: T1 T-cells are like cops, patrolling the body for bad guys which may be bacteria/viruses/even 🦀 cells. Normal cells express proteins on their surface to let the T cells knw tht they belong in the body ex: PDL1. 🦀 cells escape killing by Tcells by expressing the same PDL1. #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T2. Most patients think of vaccines in terms of prevention. In immunotherapy, cancer vaccines are used for treatment. These are often called therapeutic vaccines. #LCSM |
| Bob Steele @steele_bob RT @BrendonStilesMD: @lcsmchat Going to bring the A-game and get the A-listers out in force. #lcsm |
| #LCSM Chat @lcsmchat @RedGia Hi there! #lcsm |
| Brendon Stiles @BrendonStilesMD @kasedill @LeciaSequist Who doesn't love a good game changer!? #lcsm |
| Janet Freeman-Daily @JFreemanDaily @wildwestannie There is more than one type of checkpoint inhibitor. One types blocks the PD-1 pathway. Another blocks the CT4 pathway. Others are in development. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @BrendonStilesMD We're on T2, but Twitter is misbehaving so we're behind on our tweets. #LCSM |
| Dee Sparacio @womenofteal T2 @AmericanCancer has a great page on Immune Checkpoint inhibitors and how they work https://t.co/cCIjr2pvWm #lcsm |
| Janet Freeman-Daily @JFreemanDaily T3: How can we tell if immunotherapy will work for my cancer? #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T2. Cancer therapeutic vaccines train the immune system to recognize and eliminate cancer cells. Most are still in clinical trials but there is one approved for prostate cancer. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @wildwestannie There is more than one type of checkpoint inhibitor. One types blocks the PD-1 pathway. Another blocks the CT4 pathway. Others are in development. #LCSM |
| #LCSM Chat @lcsmchat RT @womenofteal: T2 @AmericanCancer has a great page on Immune Checkpoint inhibitors and how they work https://t.co/cCIjr2pvWm #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @womenofteal: T2 @AmericanCancer has a great page on Immune Checkpoint inhibitors and how they work https://t.co/cCIjr2pvWm #lcsm |
| Lisa Rezende @LisaRezende1 T2. This therapeutic vaccine is more complicated than a shot. Immune cells are isolated from a patient's blood, then trained to recognize the cancer. Finally, the cells are given back to the patient so they will attack the cancer. #LCSM |
| Bob Steele @steele_bob RT @womenofteal: T2 @AmericanCancer has a great page on Immune Checkpoint inhibitors and how they work https://t.co/cCIjr2pvWm #lcsm |
| Loves Mashed Potatoes @glostaMAssachu RT @JFreemanDaily: @wildwestannie There is more than one type of checkpoint inhibitor. One types blocks the PD-1 pathway. Another blocks the CT4 pathway. Others are in development. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @wildwestannie There is more than one type of checkpoint inhibitor. One types blocks the PD-1 pathway. Another blocks the CT4 pathway. Others are in development. #LCSM |
| Aparna Hegde, MD @notahedge T2 There are diff types of immunotherapies. But all of them leverage our own immune system to kill 🦀 #LCSM |
| KC Dill @kasedill RT @JFreemanDaily: T3: T3: How can we tell if immunotherapy will work for my cancer? #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T2. This therapeutic vaccine is more complicated than a shot. Immune cells are isolated from a patient's blood, then trained to recognize the cancer. Finally, the cells are given back to the patient so they will attack the cancer. #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T2. This therapeutic vaccine is more complicated than a shot. Immune cells are isolated from a patient's blood, then trained to recognize the cancer. Finally, the cells are given back to the patient so they will attack the cancer. #LCSM |
| Brendon Stiles @BrendonStilesMD T2. Lots of great drugs, each used in sometimes different contexts. Many have not been tried head to head but there are probably differences in efficacy. #lcsm |
| Bob Steele @steele_bob RT @notahedge: T2 There are diff types of immunotherapies. But all of them leverage our own immune system to kill 🦀 #LCSM |
| #LCSM Chat @lcsmchat @Dollybrad Hi MaryAnn! #lcsm |
| #LCSM Chat @lcsmchat RT @notahedge: T2 There are diff types of immunotherapies. But all of them leverage our own immune system to kill 🦀 #LCSM |
| Lisa Rezende @LisaRezende1 T2. Checkpoint inhibitors are what we see most often in the headlines today. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Lots of great drugs, each used in sometimes different contexts. Many have not been tried head to head but there are probably differences in efficacy. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @LisaRezende1 CimaVax is a therapeutic vaccine in clinical trials for #lungcancer. It's approved in Cuba and some other countries, but is still being evaluated in the US. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3: T3: How can we tell if immunotherapy will work for my cancer? #LCSM |
| Dee Sparacio @womenofteal RT @LisaRezende1: T2. Most patients think of vaccines in terms of prevention. In immunotherapy, cancer vaccines are used for treatment. These are often called therapeutic vaccines. #LCSM |
| Brendon Stiles @BrendonStilesMD T3. Great question for which we need more research. Tumor PD-L1 expression is best segregator now, but not perfect. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @womenofteal @AmericanCancer Thanks Dee! #LCSM |
| Brendon Stiles @BrendonStilesMD T3. How many total mutations your tumor has (TMB) may also be an important predictor. #lcsm |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T2. Checkpoint inhibitors are what we see most often in the headlines today. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @LisaRezende1 CimaVax is a therapeutic vaccine in clinical trials for #lungcancer. It's approved in Cuba and some other countries, but is still being evaluated in the US. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Great question for which we need more research. Tumor PD-L1 expression is best segregator now, but not perfect. #lcsm |
| Lisa Rezende @LisaRezende1 So happy to see everyone sharing links- Twitter is not letting me cut and past right now so I can't provide the links I've collected! #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist @JFreemanDaily T3 This is the million dollar question. We have a biomarker that predicts likelihood of response to CPI (PDL1 staining) but it is a mediocre predictor - nothing like the biomarkers for targeted therapy. Good news: in lung cancer chemo + IO works well regardless of PD1. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. How many total mutations your tumor has (TMB) may also be an important predictor. #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T3. How many total mutations your tumor has (TMB) may also be an important predictor. #lcsm |
| #LCSM Chat @lcsmchat RT @LisaRezende1: So happy to see everyone sharing links- Twitter is not letting me cut and past right now so I can't provide the links I've collected! #LCSM |
| Stephen V Liu, MD @StephenVLiu T3: Unfortunately we don’t have a perfect predictor of whether immunotherapy will work or not. For now, it should be part of standard therapy for anyone with stage 4 lung cancer that does not have a driver mutation like EGFR or ALK #LCSM |
| Dee Sparacio @womenofteal Yes we hear more and more about TMB . #lcsm |
| Aparna Hegde, MD @notahedge T2 Broadly, 1. Vaccines 2. CART cell therapies 3. Checkpoint inhibitors. Several other modulators of the immune system are being researched. #LCSM |
 | gilberto lopes @GlopesMd RT @StephenVLiu: By understanding how cancers escape immune surveillance, we can develop strategies to restore immune control. Checkpoint inhibitors are just the start! #LCSM |
| Brendon Stiles @BrendonStilesMD T3. Unfortunately, right now if you have EGFR+ or ALK+ lung cancer, immuno probably WON'T work. Lots of trials to figure out ways to improve this. #lcsm |
| SunshineKK @SunshineKK68 How does Keytruda enhance chemotherapy even without PD-L1 expression? #lcsm |
| #LCSM Chat @lcsmchat @LisaRezende1 We can work on the links after the chat. Thanks for trying. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Jury is still out on it. #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @JFreemanDaily T3 This is the million dollar question. We have a biomarker that predicts likelihood of response to CPI (PDL1 staining) but it is a mediocre predictor - nothing like the biomarkers for targeted therapy. Good news: in lung cancer chemo + IO works well regardless of PD1. #LCSM |
| #LCSM Chat @lcsmchat RT @StephenVLiu: T3: T3: Unfortunately we don’t have a perfect predictor of whether immunotherapy will work or not. For now, it should be part of standard therapy for anyone with stage 4 lung cancer that does not have a driver mutation like EGFR or ALK #LCSM |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD PD-L1 pathway (same as PD-1 pathway) is the best immunotherapy for #lungcancer, but not necessarily for ALL cancers. Remember, this is a collaborative chat across cancer types. #LCSM |
| #LCSM Chat @lcsmchat RT @notahedge: T2 Broadly, 1. Vaccines 2. CART cell therapies 3. Checkpoint inhibitors. Several other modulators of the immune system are being researched. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Unfortunately, right now if you have EGFR+ or ALK+ lung cancer, immuno probably WON'T work. Lots of trials to figure out ways to improve this. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Lots of questions still to answer. #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Jury is still out on it. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @StephenVLiu: T3: T3: Unfortunately we don’t have a perfect predictor of whether immunotherapy will work or not. For now, it should be part of standard therapy for anyone with stage 4 lung cancer that does not have a driver mutation like EGFR or ALK #LCSM |
| Lisa Rezende @LisaRezende1 T2. In normal conditions, the checkpoint acts as "brakes" to keep the immune system from attacking healthy cells. When some cancer cells escape, they use those "brakes" to evade the immune system. #LCSM |
| Aparna Hegde, MD @notahedge T2 antibiotics are to bacteria/virus/fungi what chemotherapy is to cancer. They directly attack the cells. #LCSM |
| #LCSM Chat @lcsmchat RT @SunshineKK68: How does Keytruda enhance chemotherapy even without PD-L1 expression? #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @BrendonStilesMD PD-L1 pathway (same as PD-1 pathway) is the best immunotherapy for #lungcancer, but not necessarily for ALL cancers. Remember, this is a collaborative chat across cancer types. #LCSM |
| Brendon Stiles @BrendonStilesMD @SunshineKK68 Another great question. More likely that chemo may enhance the immune response by killing some cells and exposing tumor proteins which the immune system can recognize. #lcsm |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T2. In normal conditions, the checkpoint acts as "brakes" to keep the immune system from attacking healthy cells. When some cancer cells escape, they use those "brakes" to evade the immune system. #LCSM |
| #LCSM Chat @lcsmchat RT @notahedge: T2 antibiotics are to bacteria/virus/fungi what chemotherapy is to cancer. They directly attack the cells. #LCSM |
| Bob Steele @steele_bob RT @notahedge: T2 antibiotics are to bacteria/virus/fungi what chemotherapy is to cancer. They directly attack the cells. #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist @BrendonStilesMD Very true @BrendonStilesMD and lack of IO efficacy probably extrapolates to other oncogene-driven cancers like MET e14, ROS, RET #LCSM |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @notahedge: T2 antibiotics are to bacteria/virus/fungi what chemotherapy is to cancer. They directly attack the cells. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Testing is likely going to be valuable in the future as we learn more. #lcsm |
| Dee Sparacio @womenofteal RT @BrendonStilesMD: @SunshineKK68 Another great question. More likely that chemo may enhance the immune response by killing some cells and exposing tumor proteins which the immune system can recognize. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @LeciaSequist: @BrendonStilesMD Very true @BrendonStilesMD and lack of IO efficacy probably extrapolates to other oncogene-driven cancers like MET e14, ROS, RET #LCSM |
| #LCSM Chat @lcsmchat @lcsmchat The impact created by the immune therapy in treatment of lung cancer is remarkable. While its effectiveness in bladder cancer and cervical cancer is also proven, its utility for breast cancer is waiting FDA approval. (From @israhkhan) #lcsm |
| Lisa Rezende @LisaRezende1 T3. Tumor DNA tests that look for defects in the cancer cell's ability to repair mistakes in DNA are also used to indicate that a cancer might respond to immunotherapy. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @SunshineKK68 Another great question. More likely that chemo may enhance the immune response by killing some cells and exposing tumor proteins which the immune system can recognize. #lcsm |
| Aparna Hegde, MD @notahedge RT @LeciaSequist: @JFreemanDaily T3 This is the million dollar question. We have a biomarker that predicts likelihood of response to CPI (PDL1 staining) but it is a mediocre predictor - nothing like the biomarkers for targeted therapy. Good news: in lung cancer chemo + IO works well regardless of PD1. #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @BrendonStilesMD Very true @BrendonStilesMD and lack of IO efficacy probably extrapolates to other oncogene-driven cancers like MET e14, ROS, RET #LCSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Testing is likely going to be valuable in the future as we learn more. #lcsm |
| Loves Mashed Potatoes @glostaMAssachu RT @LisaRezende1: T2. In normal conditions, the checkpoint acts as "brakes" to keep the immune system from attacking healthy cells. When some cancer cells escape, they use those "brakes" to evade the immune system. #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T3. Tumor DNA tests that look for defects in the cancer cell's ability to repair mistakes in DNA are also used to indicate that a cancer might respond to immunotherapy. #LCSM |
| KC Dill @kasedill @BrendonStilesMD @SunshineKK68 I keep forgetting #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Tumor microenvironment probably plays a role. Not yet completely defined. #lcsm |
| Bob Steele @steele_bob From trial results, most folks have multiple driver mutations. Have seen pts with up to 15 mutations. That's got to make immuno tough #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @lcsmchat: @lcsmchat The impact created by the immune therapy in treatment of lung cancer is remarkable. While its effectiveness in bladder cancer and cervical cancer is also proven, its utility for breast cancer is waiting FDA approval. (From @israhkhan) #lcsm |
| Brendon Stiles @BrendonStilesMD Was at a great panel for @AstraZeneca today with @redsoxdoc11 and @benlevylungdoc today discussing immunotherapy and EGFR targeted therapy. #lcsm https://t.co/CvRYUm4hxq |
| Stephen V Liu, MD @StephenVLiu @LeciaSequist @BrendonStilesMD Definitely @LeciaSequist, with the possible exception being BRAF. But more study is needed #LCSM |
| Bob Steele @steele_bob RT @TimAllenMDJD: Tumor microenvironment probably plays a role. Not yet completely defined. #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Tumor microenvironment probably plays a role. Not yet completely defined. #lcsm |
| #LCSM Chat @lcsmchat RT @steele_bob: From trial results, most folks have multiple driver mutations. Have seen pts with up to 15 mutations. That's got to make immuno tough #lcsm |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @LeciaSequist @BrendonStilesMD Definitely @LeciaSequist, with the possible exception being BRAF. But more study is needed #LCSM |
| Brendon Stiles @BrendonStilesMD @kasedill @SunshineKK68 Provocative question. PACIFIC trial and a trial we have underway show a signal that radiation may help prime immune response, but data still early and needs more study. #lcsm |
| Janet Freeman-Daily @JFreemanDaily T3: The upshot is that we have some tests that are designed to help determine those for whom immunotherapy will work, but they're not very accurate yet. We need better biomarkers. #LCSM |
| Lisa Rezende @LisaRezende1 T3. There is a checkpoint inhibitor approved for all tumors that have high microsatellite instability, regardless of type. Cancer associated with Lynch syndrome have this defect. #LCSM |
| #LCSM Chat @lcsmchat "Will being pretreated with IMRT enhance the response as well?" (From @kasedill) #lcsm |
| Bob Steele @steele_bob Clearly it's a multifactorial microenvironment. Hard computational issues. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @kasedill @SunshineKK68 Provocative question. PACIFIC trial and a trial we have underway show a signal that radiation may help prime immune response, but data still early and needs more study. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3: T3: The upshot is that we have some tests that are designed to help determine those for whom immunotherapy will work, but they're not very accurate yet. We need better biomarkers. #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T3. There is a checkpoint inhibitor approved for all tumors that have high microsatellite instability, regardless of type. Cancer associated with Lynch syndrome have this defect. #LCSM |
| Brendon Stiles @BrendonStilesMD @TimAllenMDJD Key area of work for pathology. Has to be important! #lcsm |
| #LCSM Chat @lcsmchat RT @steele_bob: Clearly it's a multifactorial microenvironment. Hard computational issues. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @steele_bob Actually, it's rare for people to have multiple DRIVER mutations. There are many other mutations that are not consider the primary driver of the cancer. People with more mutations seem to do better on immunotherapy, which is why people are studying Tumor Mutation Burden. #LCSM |
 | Cecília Arraes @CeciliaArraes RT @JTOonline: In this JTO Editor's Choice, Eguchi and colleagues evaluate the association between the outcome of patients with STAS receiving sublobar resection or lobectomy. #LCSM https://t.co/3amMOznER4 |
| Janet Freeman-Daily @JFreemanDaily T4: What are the downsides of immunotherapy? #LCSM |
 | CU Cancer Center @CUCancerCenter Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer https://t.co/rsYIQtbTlp #LCSM #lungcancer @IASLC https://t.co/UL7VjbkjCT |
| Dee Sparacio @womenofteal T3 @FacingOurRisk also describes immunotherapies - monoclonal antibodies, check pt inhibitors, vaccines etc https://t.co/y0uwjInH81 #lcsm #gyncsm |
| Lisa Rezende @LisaRezende1 T3. NCCN patient guidelines have useful information on currently approved therapies for different cancer, written in language patients can understand. These handbooks can help patients discuss options with their providers. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @steele_bob Actually, it's rare for people to have multiple DRIVER mutations. There are many other mutations that are not consider the primary driver of the cancer. People with more mutations seem to do better on immunotherapy, which is why people are studying Tumor Mutation Burden. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4: T4: What are the downsides of immunotherapy? #LCSM |
| Cecília Arraes @CeciliaArraes RT @IASLC: “Cancer Statistics, 2019,” @AmericanCancer's report on cancer rates/trends, shows a 27% drop in the overall cancer death rate in the U.S. f/ 1991 to 2016. However, socioeconomic inequalities are widening. What do you think of the report? #LCSM https://t.co/LbPHFHaPor |
| #LCSM Chat @lcsmchat RT @womenofteal: T3 @FacingOurRisk also describes immunotherapies - monoclonal antibodies, check pt inhibitors, vaccines etc https://t.co/y0uwjInH81 #lcsm #gyncsm |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T3. NCCN patient guidelines have useful information on currently approved therapies for different cancer, written in language patients can understand. These handbooks can help patients discuss options with their providers. #LCSM |
| Lisa Rezende @LisaRezende1 T3. The NCCN patient guidelines for melanoma and lung cancer both have nice discussions of approved immunotherapies. #LCSM |
| Brendon Stiles @BrendonStilesMD T4. Can't let the hype set false expectations. Important to recognize that most patients may not respond. But also important to have hope and excitement. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @lcsmchat @kasedill Several studies are examining the value of combining radiation therapy with immunotherapy. Looks promising, but jury's still out. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T4: T4: What are the downsides of immunotherapy? #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: @TimAllenMDJD Key area of work for pathology. Has to be important! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @steele_bob: Clearly it's a multifactorial microenvironment. Hard computational issues. #lcsm |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T3. The NCCN patient guidelines for melanoma and lung cancer both have nice discussions of approved immunotherapies. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Can't let the hype set false expectations. Important to recognize that most patients may not respond. But also important to have hope and excitement. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @lcsmchat: "Will being pretreated with IMRT enhance the response as well?" (From @kasedill) #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @lcsmchat @kasedill Several studies are examining the value of combining radiation therapy with immunotherapy. Looks promising, but jury's still out. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T3: T3: The upshot is that we have some tests that are designed to help determine those for whom immunotherapy will work, but they're not very accurate yet. We need better biomarkers. #LCSM |
| Janet Freeman-Daily @JFreemanDaily @LisaRezende1 NCCN Patient Guidelines are here: https://t.co/rxLWK1uLJL #LCSM |
| Brendon Stiles @BrendonStilesMD T4. IO has a whole different set of immune related side effects. Many physicians may not be as aware. Important to recognize and treat early. #lcsm |
| Bob Steele @steele_bob I put together Excel workbook with lung cancer gene mutations reported in 11 trials. Let me know if you want a copy. #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist @JFreemanDaily T4 Two major downsides I see everyday in clinic: IO doesn't work for everyone (which is very disappointing to folks given the hype) and the side effects, which don't happen to everyone but can in rare cases be quite serious #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @LisaRezende1 NCCN Patient Guidelines are here: @LisaRezende1 NCCN Patient Guidelines are here: https://t.co/rxLWK1uLJL #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. IO has a whole different set of immune related side effects. Many physicians may not be as aware. Important to recognize and treat early. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @LisaRezende1 NCCN Patient Guidelines are here: @LisaRezende1 NCCN Patient Guidelines are here: https://t.co/rxLWK1uLJL #LCSM |
| KC Dill @kasedill @steele_bob Bob count me in #LCSM |
| Brendon Stiles @BrendonStilesMD T4. What do medical oncologists think about the idea of hyperprogression? A very small proportion of patients may have rapid progression of disease. #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @JFreemanDaily T4 Two major downsides I see everyday in clinic: @JFreemanDaily T4 Two major downsides I see everyday in clinic: IO doesn't work for everyone (which is very disappointing to folks given the hype) and the side effects, which don't happen to everyone but can in rare cases be quite serious #LCSM |
| Lisa Rezende @LisaRezende1 T4. Many articles on immunotherapy describe "harnessing" the immune system. Some patients describe it as "unleashing." This very active immune response can have side effects #LCSM |
| Cecília Arraes @CeciliaArraes RT @JCO_ASCO: Updated analysis of KEYNOTE-024 - pembrolizumab vs platinum-based chemo for advanced NSCLC https://t.co/cy67qos7Be #lcsm #immunoonc https://t.co/txkubN1xbE |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. What do medical oncologists think about the idea of hyperprogression? A very small proportion of patients may have rapid progression of disease. #lcsm |
| Brendon Stiles @BrendonStilesMD @LeciaSequist @StephenVLiu #lcsm |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T4. Many articles on immunotherapy describe "harnessing" the immune system. Some patients describe it as "unleashing." This very active immune response can have side effects #LCSM |
| Dee Sparacio @womenofteal @JFreemanDaily T4 Side -effects comes to mind . @SITcancer has come up with recommendations "most side effects from checkpoint inhibitors are mild to moderate and can be treated with drugs that temporarily suppress the immune system. " #lcsm .https://t.co/JVnyZBQx9o |
| KC Dill @kasedill RT @LisaRezende1: T4. Many articles on immunotherapy describe "harnessing" the immune system. Some patients describe it as "unleashing." This very active immune response can have side effects #LCSM |
| Janet Freeman-Daily @JFreemanDaily T4: Important to recognized that immunotherapy is not without side effects. Some people have few side effects. Some have severe side effects, which may be permanent. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #EvidenceBasedMedicine #SkipTheHype #PatientsFirst #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @womenofteal: @JFreemanDaily T4 Side -effects comes to mind . @SITcancer has come up with recommendations "most side effects from checkpoint inhibitors are mild to moderate and can be treated with drugs that temporarily suppress the immune system. " #lcsm .https://t.co/JVnyZBQx9o |
| Loves Mashed Potatoes @glostaMAssachu RT @BrendonStilesMD: T4. What do medical oncologists think about the idea of hyperprogression? A very small proportion of patients may have rapid progression of disease. #lcsm |
| #LCSM Chat @lcsmchat RT @womenofteal: @JFreemanDaily T4 Side -effects comes to mind . @SITcancer has come up with recommendations "most side effects from checkpoint inhibitors are mild to moderate and can be treated with drugs that temporarily suppress the immune system. " #lcsm .https://t.co/JVnyZBQx9o |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4: T4: Important to recognized that immunotherapy is not without side effects. Some people have few side effects. Some have severe side effects, which may be permanent. #LCSM |
| Bob Steele @steele_bob Seems that many non-Driver mutations are catalysts. #lcsm |
| Lisa Rezende @LisaRezende1 T4. ASCO and NCCN have guidelines on recognizing and managing the side effects of immunotherapies. A list of side effects is published on the ASCO https://t.co/w1RA7HdPrv site (I still can't paste links!) #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @JFreemanDaily T4 Two major downsides I see everyday in clinic: @JFreemanDaily T4 Two major downsides I see everyday in clinic: IO doesn't work for everyone (which is very disappointing to folks given the hype) and the side effects, which don't happen to everyone but can in rare cases be quite serious #LCSM |
| Anita Figueras @scifiknitter RT @JFreemanDaily: @LisaRezende1 NCCN Patient Guidelines are here: @LisaRezende1 NCCN Patient Guidelines are here: https://t.co/rxLWK1uLJL #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T4: T4: Important to recognized that immunotherapy is not without side effects. Some people have few side effects. Some have severe side effects, which may be permanent. #LCSM |
| Brendon Stiles @BrendonStilesMD Have to drop off. Sorry for the brief cameo. Get ready for February!!! @lcsmchat #lcsm |
| Aparna Hegde, MD @notahedge @lcsmchat @kasedill It may be so due to a phenomenon called abscopal effect. XRT to 1 lesion may result in shrinkage of other lesions elsewhere in the body. This is believed to be due to XRT stimulating the immune system via a number of mechanisms. Combining IO with XRT has strong rationale #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T4. ASCO and NCCN have guidelines on recognizing and managing the side effects of immunotherapies. A list of side effects is published on the ASCO https://t.co/w1RA7HdPrv site (I still can't paste links!) #LCSM |
| #LCSM Chat @lcsmchat RT @notahedge: @lcsmchat @kasedill It may be so due to a phenomenon called abscopal effect. XRT to 1 lesion may result in shrinkage of other lesions elsewhere in the body. This is believed to be due to XRT stimulating the immune system via a number of mechanisms. Combining IO with XRT has strong rationale #LCSM |
| KC Dill @kasedill @BrendonStilesMD @lcsmchat Thanks as always #LCSM |
 | Gia Sonata @RedGia @BrendonStilesMD #lcsm - Is this the same as "pseudo-progression"? |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @notahedge: @lcsmchat @kasedill It may be so due to a phenomenon called abscopal effect. XRT to 1 lesion may result in shrinkage of other lesions elsewhere in the body. This is believed to be due to XRT stimulating the immune system via a number of mechanisms. Combining IO with XRT has strong rationale #LCSM |
| Lisa Rezende @LisaRezende1 T4. I agree hype can be frustrating for patients. It is important to remember we aren't there yet for all cancers or all patients with a cancer that has an approved IO. Health care providers need patients understand if it is an option for them #LCSM |
| Aparna Hegde, MD @notahedge @lcsmchat @kasedill Trials testing this combination are underway. The Pacific trial showed that pts who started durvalumab within 14 days of completing XRT had better outcomes.#LCSM |
 | Vamsi Velcheti, MD MBA @VamsiVelcheti Joining from New York @nyulangone #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T4. I agree hype can be frustrating for patients. It is important to remember we aren't there yet for all cancers or all patients with a cancer that has an approved IO. Health care providers need patients understand if it is an option for them #LCSM |
| #LCSM Chat @lcsmchat RT @notahedge: @lcsmchat @kasedill Trials testing this combination are underway. The Pacific trial showed that pts who started durvalumab within 14 days of completing XRT had better outcomes.#LCSM |
| Anita Figueras @scifiknitter RT @LisaRezende1: T4. Many articles on immunotherapy describe "harnessing" the immune system. Some patients describe it as "unleashing." This very active immune response can have side effects #LCSM |
| Janet Freeman-Daily @JFreemanDaily @RedGia @BrendonStilesMD Hyperprogression and pseudo progression are different. Hyperprogression means the cancer growth accelerates. Pseudo-progression is when the tumor temporarily seems larger because immune system cells are drawn into the tumor and cause inflammation. #LCSM |
| #LCSM Chat @lcsmchat @VamsiVelcheti @nyulangone Welcome! #lcsm |
| Dee Sparacio @womenofteal RT @JFreemanDaily: @RedGia @BrendonStilesMD Hyperprogression and pseudo progression are different. Hyperprogression means the cancer growth accelerates. Pseudo-progression is when the tumor temporarily seems larger because immune system cells are drawn into the tumor and cause inflammation. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @LisaRezende1: T4. I agree hype can be frustrating for patients. It is important to remember we aren't there yet for all cancers or all patients with a cancer that has an approved IO. Health care providers need patients understand if it is an option for them #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @RedGia @BrendonStilesMD Hyperprogression and pseudo progression are different. Hyperprogression means the cancer growth accelerates. Pseudo-progression is when the tumor temporarily seems larger because immune system cells are drawn into the tumor and cause inflammation. #LCSM |
| KC Dill @kasedill RT @JFreemanDaily: @RedGia @BrendonStilesMD Hyperprogression and pseudo progression are different. Hyperprogression means the cancer growth accelerates. Pseudo-progression is when the tumor temporarily seems larger because immune system cells are drawn into the tumor and cause inflammation. #LCSM |
| Anita Figueras @scifiknitter RT @JFreemanDaily: @RedGia @BrendonStilesMD Hyperprogression and pseudo progression are different. Hyperprogression means the cancer growth accelerates. Pseudo-progression is when the tumor temporarily seems larger because immune system cells are drawn into the tumor and cause inflammation. #LCSM |
| Janet Freeman-Daily @JFreemanDaily T5: How can I find the right immunotherapy clinical trial for me? #LCSM |
| Lisa Rezende @LisaRezende1 T4. It is important for patients on immunotherapy to inform any health care provider (such as emergency room providers) that they are on an IO and not traditional chemo. The side effects are different. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T5: T5: How can I find the right immunotherapy clinical trial for me? #LCSM |
| Janet Freeman-Daily @JFreemanDaily T5: search for I/O clinical trials at (1) NCI database https://t.co/cUZe8RmROH, (2) clinical trial finders offered by disease-specific advocacy groups, (3) Cancer Research Institute https://t.co/w5R0ObQtVg #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T5: T5: How can I find the right immunotherapy clinical trial for me? #LCSM |
| Janet Freeman-Daily @JFreemanDaily T5: Disease-specific online communities often have knowledgeable advocates who can help you learn about immunotherapy and clinical trials for your cancer #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T4. It is important for patients on immunotherapy to inform any health care provider (such as emergency room providers) that they are on an IO and not traditional chemo. The side effects are different. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T5: T5: search for I/O clinical trials at (1) NCI database https://t.co/cUZe8RmROH, (2) clinical trial finders offered by disease-specific advocacy groups, (3) Cancer Research Institute https://t.co/w5R0ObQtVg #LCSM |
| KC Dill @kasedill RT @JFreemanDaily: T5: T5: search for I/O clinical trials at (1) NCI database https://t.co/cUZe8RmROH, (2) clinical trial finders offered by disease-specific advocacy groups, (3) Cancer Research Institute https://t.co/w5R0ObQtVg #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T5: T5: Disease-specific online communities often have knowledgeable advocates who can help you learn about immunotherapy and clinical trials for your cancer #LCSM |
| Janet Freeman-Daily @JFreemanDaily T5: It’s helpful to discuss trial options with your oncologist, or during a second opinion visit at an academic cancer center that conducts research in your cancer (like an NCI SPORE program -- see https://t.co/9isPR2TclM ) #LCSM |
| Lisa Rezende @LisaRezende1 T4. Some groups and companies have developed treatment-specific wallet cards that patients can carry to inform other providers of their treatment and the side effects they can expect. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T5: T5: Disease-specific online communities often have knowledgeable advocates who can help you learn about immunotherapy and clinical trials for your cancer #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T5: T5: search for I/O clinical trials at (1) NCI database https://t.co/cUZe8RmROH, (2) clinical trial finders offered by disease-specific advocacy groups, (3) Cancer Research Institute https://t.co/w5R0ObQtVg #LCSM |
 | JC @stu12bball @lcsmchat hello all new to the forum. Dad recently diagnosed lung cancer stage IV. He’s PD-L1. Oncologist recommending standard first line treatment. Will consider PD-L1 immunotherapy as second line treatment. Any recommendation from the audience #LCSM |
| Aparna Hegde, MD @notahedge RT @JFreemanDaily: T5: T5: Disease-specific online communities often have knowledgeable advocates who can help you learn about immunotherapy and clinical trials for your cancer #LCSM |
| Aparna Hegde, MD @notahedge RT @JFreemanDaily: T5: T5: search for I/O clinical trials at (1) NCI database https://t.co/cUZe8RmROH, (2) clinical trial finders offered by disease-specific advocacy groups, (3) Cancer Research Institute https://t.co/w5R0ObQtVg #LCSM |
| Vamsi Velcheti, MD MBA @VamsiVelcheti @BrendonStilesMD It is still unclear if hyper progression is a real phenomenon.. recent data by @drgandara at @myESMO on the OAK trial showed similar rates of ‘rapid’ progression in chemo and IO arms.. suspect what we are calling hyper progression may just be poor/aggressive biology #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T5: T5: It’s helpful to discuss trial options with your oncologist, or during a second opinion visit at an academic cancer center that conducts research in your cancer (like an NCI SPORE program -- see https://t.co/9isPR2TclM ) #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T5: T5: It’s helpful to discuss trial options with your oncologist, or during a second opinion visit at an academic cancer center that conducts research in your cancer (like an NCI SPORE program -- see https://t.co/9isPR2TclM ) #LCSM |
| Dee Sparacio @womenofteal T5 Could also try the patient recruitment page for the NIH https://t.co/EHCRKc91Vi #lcsm |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T4. Some groups and companies have developed treatment-specific wallet cards that patients can carry to inform other providers of their treatment and the side effects they can expect. #LCSM |
| Janet Freeman-Daily @JFreemanDaily Clinical trial finders recommended by ASCO's https://t.co/bZg1FNdtnK site https://t.co/Z1M9AQ6k9K •Emerging Med https://t.co/UakfAcMNQh •Lazarex Cancer Foundation https://t.co/TCGdlixibj #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist @BrendonStilesMD @BrendonStilesMD the concept of hyperprogression on IO is controversial and some think it doesn't exist. I tend to think that it does and that I've seen it a few times - where IO seems to "unleash" an entirely different tumor behavior #LCSM |
| Lisa Rezende @LisaRezende1 T5. For those with hereditary cancers, @FacingOurRisk has a clinical trial search tool for hereditary breast, ovarian, prostate, and pancreatic cancers. #LCSM |
| Dee Sparacio @womenofteal Yes. Cards especially important for those in clinical trials. #lcsm |
| Stephen V Liu, MD @StephenVLiu RT @JFreemanDaily: T5: T5: search for I/O clinical trials at (1) NCI database https://t.co/cUZe8RmROH, (2) clinical trial finders offered by disease-specific advocacy groups, (3) Cancer Research Institute https://t.co/w5R0ObQtVg #LCSM |
| KC Dill @kasedill RT @JFreemanDaily: T5: T5: It’s helpful to discuss trial options with your oncologist, or during a second opinion visit at an academic cancer center that conducts research in your cancer (like an NCI SPORE program -- see https://t.co/9isPR2TclM ) #LCSM |
| #LCSM Chat @lcsmchat RT @stu12bball: @lcsmchat hello all new to the forum. Dad recently diagnosed lung cancer stage IV. He’s PD-L1. Oncologist recommending standard first line treatment. Will consider PD-L1 immunotherapy as second line treatment. Any recommendation from the audience #LCSM |
| Aparna Hegde, MD @notahedge RT @VamsiVelcheti: @BrendonStilesMD It is still unclear if hyper progression is a real phenomenon.. recent data by @drgandara at @myESMO on the OAK trial showed similar rates of ‘rapid’ progression in chemo and IO arms.. suspect what we are calling hyper progression may just be poor/aggressive biology #LCSM |
| Lisa Rezende @LisaRezende1 T5. Patients can always talk to their health care team about trials, but unfortunately, the best trial for their cancer might not be available locally. #LCSM |
| Stephen V Liu, MD @StephenVLiu @stu12bball @lcsmchat For lung cancer, standard therapy includes immunotherapy as part of initial therapy. Would strongly advise against waiting to implement. Best outsvimes are with first line use. #LCSM |
| #LCSM Chat @lcsmchat RT @VamsiVelcheti: @BrendonStilesMD It is still unclear if hyper progression is a real phenomenon.. recent data by @drgandara at @myESMO on the OAK trial showed similar rates of ‘rapid’ progression in chemo and IO arms.. suspect what we are calling hyper progression may just be poor/aggressive biology #LCSM |
| #LCSM Chat @lcsmchat RT @womenofteal: T5 Could also try the patient recruitment page for the NIH https://t.co/EHCRKc91Vi #lcsm |
| KC Dill @kasedill @JFreemanDaily Bookmarking for future reference. Great info Janet.. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Clinical trial finders recommended by ASCO's https://t.co/bZg1FNdtnK site https://t.co/Z1M9AQ6k9K •Emerging Med https://t.co/UakfAcMNQh •Lazarex Cancer Foundation https://t.co/TCGdlixibj #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @BrendonStilesMD @BrendonStilesMD the concept of hyperprogression on IO is controversial and some think it doesn't exist. I tend to think that it does and that I've seen it a few times - where IO seems to "unleash" an entirely different tumor behavior #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T5. For those with hereditary cancers, @FacingOurRisk has a clinical trial search tool for hereditary breast, ovarian, prostate, and pancreatic cancers. #LCSM |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @stu12bball @lcsmchat For lung cancer, standard therapy includes immunotherapy as part of initial therapy. Would strongly advise against waiting to implement. Best outsvimes are with first line use. #LCSM |
 | Gina @EAustin1969 RT @JFreemanDaily: T5: T5: Disease-specific online communities often have knowledgeable advocates who can help you learn about immunotherapy and clinical trials for your cancer #LCSM |
| Dee Sparacio @womenofteal Very Informative Chat. Thanks @JFreemanDaily for the invite. Looking forward to another joint chat in the summer. Got to run - two dogs need one more walk in the cold and windy outdoors. #lcsm |
| Janet Freeman-Daily @JFreemanDaily We’re in our final minutes - closing thoughts? #LCSM |
 | Inspire @InspireIsHealth RT @JFreemanDaily: T5: T5: search for I/O clinical trials at (1) NCI database https://t.co/cUZe8RmROH, (2) clinical trial finders offered by disease-specific advocacy groups, (3) Cancer Research Institute https://t.co/w5R0ObQtVg #LCSM |
| Anita Figueras @scifiknitter RT @LisaRezende1: T4. It is important for patients on immunotherapy to inform any health care provider (such as emergency room providers) that they are on an IO and not traditional chemo. The side effects are different. #LCSM |
 | Stacey Tinianov (she/her) MPH, BCPA @coffeemommy Missed all but the last 2 minutes of the mixed group tweet chat on #Immunotherapy hosted by #LCSM. Now off to a high school music booster meeting but eager to catch up on the tweets later tonight/tomorrow. Hugs all around to the awesome advocates sharing their knowledge 💖 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @StephenVLiu: @stu12bball @lcsmchat For lung cancer, standard therapy includes immunotherapy as part of initial therapy. Would strongly advise against waiting to implement. Best outsvimes are with first line use. #LCSM |
| Anita Figueras @scifiknitter RT @JFreemanDaily: T5: T5: search for I/O clinical trials at (1) NCI database https://t.co/cUZe8RmROH, (2) clinical trial finders offered by disease-specific advocacy groups, (3) Cancer Research Institute https://t.co/w5R0ObQtVg #LCSM |
| Aparna Hegde, MD @notahedge T4 immunotherapy is not benign. Can have severe side effects that are likely more common than what has been reported. Unlike chemo, toxicities can have delayed onset affecting different organs at different time points. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Clinical trial finders recommended by ASCO's https://t.co/bZg1FNdtnK site https://t.co/Z1M9AQ6k9K •Emerging Med https://t.co/UakfAcMNQh •Lazarex Cancer Foundation https://t.co/TCGdlixibj #LCSM |
| Anita Figueras @scifiknitter RT @JFreemanDaily: T5: T5: Disease-specific online communities often have knowledgeable advocates who can help you learn about immunotherapy and clinical trials for your cancer #LCSM |
 | 🧠Julia Robertson @Ailuj_Nostrebor RT @CBlotner_: Pssttt: Pssttt: #btsm #bcsm #lcsm #ayacsm #gyncsm folks - check out this survey to develop a cancer resource for the queer community, and pass it on! |
| Bob Steele @steele_bob Would like to see this topic repeated with researcher input. #lcsm |
| Anita Figueras @scifiknitter RT @JFreemanDaily: T5: T5: It’s helpful to discuss trial options with your oncologist, or during a second opinion visit at an academic cancer center that conducts research in your cancer (like an NCI SPORE program -- see https://t.co/9isPR2TclM ) #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD It has been a privilege to participate. #LCSM |
| Janet Freeman-Daily @JFreemanDaily Thanks everyone for joining our all-cancer chat about immunotherapy! Hope you found the info helpful. We'll try to get Lisa's slides up later in a post on the https://t.co/39i0y9oxgJ site. #LCSM |
| KC Dill @kasedill @JFreemanDaily Always appreciate your moderation and the participants learned a lot tonight.. Good night all #LCSM |
| SunshineKK @SunshineKK68 Thank you Janet #lcsm |
| Lisa Rezende @LisaRezende1 T3. Some experts recommend genetic counseling and possibly testing for Lynch syndrome for patients whose tumors have microsatellite instability. If you are concerned that your cancer might be hereditary, a genetic counselor can help you decide if testing is right for you. #LCSM |
| Bob Steele @steele_bob Oops. I left out the word "more" researcher input. #lcsm |
| Christine Qiong Wu @CQiongWu I'm new for this Tweet, just 2nd time participate, still learning. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We’re in our final minutes - closing thoughts? #LCSM |
| #LCSM Chat @lcsmchat RT @notahedge: T4 immunotherapy is not benign. Can have severe side effects that are likely more common than what has been reported. Unlike chemo, toxicities can have delayed onset affecting different organs at different time points. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Thanks everyone for joining our all-cancer chat about immunotherapy! Hope you found the info helpful. We'll try to get Lisa's slides up later in a post on the https://t.co/39i0y9oxgJ site. #LCSM |
| Janet Freeman-Daily @JFreemanDaily Thanks to our special guest @LisaRezende1 for bringing her cancer communications skills to the chat! #LCSM |
| #LCSM Chat @lcsmchat RT @LisaRezende1: T3. Some experts recommend genetic counseling and possibly testing for Lynch syndrome for patients whose tumors have microsatellite instability. If you are concerned that your cancer might be hereditary, a genetic counselor can help you decide if testing is right for you. #LCSM |
| Lisa Rezende @LisaRezende1 Thanks for inviting me! #LCSM |
| Aparna Hegde, MD @notahedge IO is a great advance for cancer but doesn't benefit everyone. We need to look past the hype and redouble efforts to find predictive markers, better drugs/ drug combinations and address toxicities #LCSM |
| Loves Mashed Potatoes @glostaMAssachu Thank you Janet, really interesting and nicely explained. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Thanks to our special guest @LisaRezende1 for bringing her cancer communications skills to the chat! #LCSM |
| #LCSM Chat @lcsmchat RT @notahedge: IO is a great advance for cancer but doesn't benefit everyone. We need to look past the hype and redouble efforts to find predictive markers, better drugs/ drug combinations and address toxicities #LCSM |
| Anita Figueras @scifiknitter RT @JFreemanDaily: Clinical trial finders recommended by ASCO's https://t.co/bZg1FNdtnK site https://t.co/Z1M9AQ6k9K •Emerging Med https://t.co/UakfAcMNQh •Lazarex Cancer Foundation https://t.co/TCGdlixibj #LCSM |
| Anita Figueras @scifiknitter RT @LisaRezende1: T5. For those with hereditary cancers, @FacingOurRisk has a clinical trial search tool for hereditary breast, ovarian, prostate, and pancreatic cancers. #LCSM |
| Bob Steele @steele_bob Thanks for hosting Janet. Looking forward to the next/every bi-weekly Lung Cancer Social Media Twitter chat session. #lcsm |
 | Dr. David Tom Cooke @DavidCookeMD RT @JFreemanDaily: Thanks everyone for joining our all-cancer chat about immunotherapy! Hope you found the info helpful. We'll try to get Lisa's slides up later in a post on the https://t.co/39i0y9oxgJ site. #LCSM |
| Aparna Hegde, MD @notahedge Happy new year everyone. Great chat as always. I enjoyed participating. Thanks for organizing @JFreemanDaily #LCSM |
 | Israh Akhtar Khan @israhkhan Immunotherapy emerges as the the lifesaver to these killer cells #lcsm https://t.co/nK50D2SWzn |
| Bob Steele @steele_bob RT @israhkhan: Immunotherapy emerges as the the lifesaver to these killer cells #lcsm https://t.co/nK50D2SWzn |
| KC Dill @kasedill RT @notahedge: @lcsmchat @kasedill Trials testing this combination are underway. The Pacific trial showed that pts who started durvalumab within 14 days of completing XRT had better outcomes.#LCSM |
| Anita Figueras @scifiknitter Thank you @JFreemanDaily and @LisaRezende1 for a very interesting chat. #LCSM |
| KC Dill @kasedill @JFreemanDaily “I” learned a lot tonight.. lol thank you Janet and participants.. #LCSM |
| Janet Freeman-Daily @JFreemanDaily @RedGia So sorry you developed thyroid issues after immunotherapy. Hope steroids and other treatments are helping with that. #LCSM |
| Janet Freeman-Daily @JFreemanDaily @wi_qiong Glad you were able to join. We learn by doing! #LCSM |
#LCSM content from Twitter.